Last reviewed · How we verify
Use of teicoplanin three times a week — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Use of teicoplanin three times a week (Use of teicoplanin three times a week) — Azienda Ospedaliera di Lecco.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Use of teicoplanin three times a week TARGET | Use of teicoplanin three times a week | Azienda Ospedaliera di Lecco | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Use of teicoplanin three times a week CI watch — RSS
- Use of teicoplanin three times a week CI watch — Atom
- Use of teicoplanin three times a week CI watch — JSON
- Use of teicoplanin three times a week alone — RSS
Cite this brief
Drug Landscape (2026). Use of teicoplanin three times a week — Competitive Intelligence Brief. https://druglandscape.com/ci/use-of-teicoplanin-three-times-a-week. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab